FDA Approves First-in-Class PROTAC Degrader Vepdegestrant for ESR1-Mutated Breast Cancer, Improving Progression-Free Survival by 43%

July 26, 2026

Dana-Farber Cancer Institute USA

Overview

The U.S. FDA has approved vepdegestrant (Veppanu), a first-in-class PROTAC (Proteolysis-Targeting Chimera) degrader, for patients with ER-positive, HER2-negative metastatic breast cancer harboring ESR1 mutations. This marks the first PROTAC approved for any cancer indication. In the VERITAC-2 clinical trial, vepdegestrant reduced the risk of disease progression or death by 43% compared to fulvestrant, achieving a median progression-free survival of 5 months. This landmark approval offers a new therapeutic option for patients with resistant advanced breast cancer and solidifies the future of the Targeted Protein Degradation (TPD) field.

In Depth

Key Findings

The U.S. Food and Drug Administration (FDA) has approved vepdegestrant (Veppanu), a first-in-class PROTAC (Proteolysis-Targeting Chimera) degrader, for patients with ER-positive, HER2-negative metastatic breast cancer who harbor ESR1 mutations. This approval represents a historic milestone as the first PROTAC agent sanctioned for any cancer indication, unequivocally establishing the therapeutic efficacy of Targeted Protein Degradation (TPD) technology in oncology. The VERITAC-2 clinical trial demonstrated remarkable results, with vepdegestrant reducing the risk of disease progression or death by 43% and achieving a median progression-free survival (PFS) of 5 months, compared to the existing standard treatment, fulvestrant.

Technical and Clinical Details

Vepdegestrant operates as a PROTAC molecule, ingeniously hijacking the cell’s ubiquitin-proteasome system to degrade specific target proteins—in this case, the estrogen receptor (ER). The ER is a primary driver of growth in ER-positive breast cancers, and mutations in the ESR1 gene are frequently associated with resistance to conventional hormonal therapies.

The VERITAC-2 clinical trial enrolled patients with ER-positive, HER2-negative metastatic breast cancer who had previously received hormonal therapy and presented with ESR1 mutations. The trial results were highly compelling: vepdegestrant significantly reduced the risk of disease progression or death by a substantial 43% when compared to fulvestrant, with a median PFS of 5 months. This represents a clinically meaningful improvement for a patient population with limited treatment options and a high unmet medical need.

The mechanism of action of vepdegestrant—degrading and removing ER from the cell, rather than merely inhibiting its activity—is believed to confer efficacy even in cancer cells that have developed resistance to traditional ER inhibitors and Selective Estrogen Receptor Degraders (SERDs). This innovative approach offers a new therapeutic strategy within the landscape of hormone-sensitive breast cancer treatment.

Background and Context

Breast cancer is the most common cancer among women, with ER-positive breast cancer accounting for approximately 70% of cases. Patients with metastatic ER-positive breast cancer often undergo prolonged hormonal therapy, but the emergence of drug resistance, particularly driven by ESR1 mutations, has been a significant challenge. This resistance frequently leads to treatment failure and disease progression, creating an urgent demand for new agents with novel mechanisms of action.

PROTACs have garnered explosive attention in drug discovery research over the past few years as a new modality. The FDA approval of vepdegestrant symbolizes the successful translation of PROTAC technology from foundational research to clinical application, demonstrating that degradation-based therapies can be effective strategies even for ‘undruggable’ targets that were previously inaccessible to small molecules or antibodies.

Strategic Significance and Outlook

The approval of vepdegestrant has the potential to fundamentally transform the treatment landscape for patients with ESR1-mutated ER-positive, HER2-negative metastatic breast cancer. This success is expected to catalyze further research, development, and investment in PROTACs and the broader TPD field. In the coming years, PROTAC pipelines targeting other cancer types and diseases are anticipated to expand, leading to the emergence of more groundbreaking therapies. Vepdegestrant marks a crucial step forward in the advancement of personalized medicine and precision oncology.

Source: https://www.aacr.org/patients-caregivers/progress-against-cancer/first-in-class-protein-degrader-approved-for-esr1-mutated-breast-cancer/

Get our weekly technology intelligence — free

Receive an infographic that lets you judge at a glance whether each field’s analysis report is worth reading.

Subscribe Free — Weekly Tech Intelligence

By subscribing, you’ll receive Troy-Technical’s weekly technology intelligence newsletter.